• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Matz Gregory W

    6/7/24 5:15:33 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Matz Gregory W

    (Last) (First) (Middle)
    3655 NOBEL DRIVE
    SUITE 260

    (Street)
    SAN DIEGO CA 92122

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Dare Bioscience, Inc. [ DARE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.43 06/05/2024 A 40,000 (1) 06/05/2034 Common stock 40,000 $0.00 40,000 D
    Explanation of Responses:
    1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.
    /s/ Sabrina Martucci Johnson, Attorney-in-fact 06/07/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DARE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Dare Bioscience Inc.

      DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

      4/24/25 4:32:42 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Dare Bioscience Inc.

      DEF 14A - Dare Bioscience, Inc. (0001401914) (Filer)

      4/24/25 4:02:32 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dare Bioscience Inc. filed SEC Form 8-K: Other Events

      8-K - Dare Bioscience, Inc. (0001401914) (Filer)

      4/11/25 5:15:09 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    See more
    • Daré Bioscience Announces Executive Team and Board of Directors Changes

      SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

      1/26/24 4:30:00 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

      SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

      4/19/21 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

      5/6/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation

      Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting availability via prescription in Q4 2025 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that Sabrina Martucci Johnson, the company's President and CEO, will provide a keynote address at the Fierce Pharma Engage summit for pharma and biotech industry leaders entitled Breaking Barriers, Building Acces

      4/23/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

      Daré unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from womenDaré is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that Sabrina Martucci Johnson, the company's President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company's expanded business strategy to integrate 503B c

      4/7/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Haring-Layton Mardee

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      1/31/25 5:34:13 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      1/31/25 5:31:46 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Steele Robin Joan

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      6/7/24 5:15:38 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

      Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/7/21 12:35:25 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Dare Bioscience with a new price target

      Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      6/30/21 9:55:24 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Financials

    Live finance-specific insights

    See more
    • Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

      5/6/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

      Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today reported financial results for the year

      3/31/25 4:01:00 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximate

      3/24/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/9/22 3:43:36 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/9/22 3:43:35 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/12/21 5:13:06 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care